Structural Basis for Inhibitor Specificity in Human Poly(ADP-ribose) Polymerase-3

被引:94
作者
Lehtio, Lari [2 ]
Jemth, Ann-Sofie [1 ]
Collins, Ruairi [2 ]
Loseva, Olga [1 ]
Johansson, Andreas [2 ]
Markova, Natalia [2 ,3 ]
Hammarstrom, Martin [2 ]
Flores, Alex [2 ]
Holmberg-Schiavone, Lovisa [2 ]
Weigelt, Johan [2 ]
Helleday, Thomas [1 ,4 ]
Schuler, Herwig [2 ]
Karlberg, Tobias [2 ]
机构
[1] Stockholm Univ, Dept Genet Microbiol & Toxicol, SE-10691 Stockholm, Sweden
[2] Karolinska Inst, Dept Med Biochem & Biophys, Struct Genom Consortium, SE-17177 Stockholm, Sweden
[3] iNovacia AB, SE-11251 Stockholm, Sweden
[4] Univ Oxford, Gray Inst Radiat Oncol & Biol, Oxford OX3 7DQ, England
基金
英国惠康基金; 瑞典研究理事会; 英国医学研究理事会;
关键词
DNA-REPAIR; CATALYTIC FRAGMENT; CEREBRAL-ISCHEMIA; STABILITY; PARP-1; CELLS;
D O I
10.1021/jm900052j
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Poly(ADP-ribose) polymerases (PARPs) activate DNA repair mechanisms upon stress- and cytotoxin-induced DNA damage, and inhibition of PARP activity is a lead in cancer drug therapy. We present a structural and functional analysis of the PARP domain of human PARP-3 in complex with several inhibitors: Of these, KU0058948 is the strongest inhibitor of PARP-3, activity. The presented crystal structures highlight key features for potent inhibitor binding and suggest routes for creating isoenzyme-specific PARP inhibitors.
引用
收藏
页码:3108 / 3111
页数:4
相关论文
共 19 条
[1]   Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].
Bryant, HE ;
Schultz, N ;
Thomas, HD ;
Parker, KM ;
Flower, D ;
Lopez, E ;
Kyle, S ;
Meuth, M ;
Curtin, NJ ;
Helleday, T .
NATURE, 2005, 434 (7035) :913-917
[2]   Poly(ADP-ribose) -: The most elaborate metabolite of NAD [J].
Bürkle, A .
FEBS JOURNAL, 2005, 272 (18) :4576-4589
[3]  
Curtin Nicola J., 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S146239940500904X
[4]   Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse [J].
de Murcia, JMN ;
Ricoul, M ;
Tartier, L ;
Niedergang, C ;
Huber, A ;
Dantzer, F ;
Schreiber, V ;
Amé, JC ;
Dierich, A ;
LeMeur, M ;
Sabatier, L ;
Chambon, P ;
de Murcia, G .
EMBO JOURNAL, 2003, 22 (09) :2255-2263
[5]   Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J].
Farmer, H ;
McCabe, N ;
Lord, CJ ;
Tutt, ANJ ;
Johnson, DA ;
Richardson, TB ;
Santarosa, M ;
Dillon, KJ ;
Hickson, I ;
Knights, C ;
Martin, NMB ;
Jackson, SP ;
Smith, GCM ;
Ashworth, A .
NATURE, 2005, 434 (7035) :917-921
[6]   DNA repair pathways as targets for cancer therapy [J].
Helleday, Thomas ;
Petermann, Eva ;
Lundin, Cecilia ;
Hodgson, Ben ;
Sharma, Ricky A. .
NATURE REVIEWS CANCER, 2008, 8 (03) :193-204
[7]   A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia [J].
Iwashita, A ;
Tojo, N ;
Matsuura, S ;
Yamazaki, S ;
Kamijo, K ;
Ishida, J ;
Yamamoto, H ;
Hattori, K ;
Matsuoka, N ;
Mutoh, S .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (02) :425-436
[8]   Novel phenanthridinone inhibitors of poly(adenosine 5′-diphosphateribose) synthetase:: Potent cytoprotective and antishock agents [J].
Jagtap, P ;
Soriano, FG ;
Virág, L ;
Liaudet, L ;
Mabley, J ;
Szabó, É ;
Haskó, G ;
Marton, A ;
Lorigados, CB ;
Gallyas, F ;
Sümegi, B ;
Hoyt, DG ;
Baloglu, E ;
VanDuzer, J ;
Salzman, AL ;
Southan, GJ ;
Szabó, C .
CRITICAL CARE MEDICINE, 2002, 30 (05) :1071-1082
[9]  
Kinoshita T, 2004, FEBS LETT, V556, P43, DOI [10.1016/S0014-5793(03)01362-0, 10.5940/jcrsj.46.421]
[10]   Zinc binding catalytic domain of human tankyrase 1 [J].
Lehtioe, Lari ;
Collins, Ruairi ;
van den Berg, Susanne ;
Johansson, Andreas ;
Dahlgren, Lars-Goeran ;
Hammarstroem, Martin ;
Helleday, Thomas ;
Holmberg-Schiavone, Lovisa ;
Karlberg, Tobias ;
Weigelt, Johan .
JOURNAL OF MOLECULAR BIOLOGY, 2008, 379 (01) :136-145